Literature DB >> 30087177

G protein signaling-biased agonism at the κ-opioid receptor is maintained in striatal neurons.

Jo-Hao Ho1, Edward L Stahl1, Cullen L Schmid1, Sarah M Scarry2, Jeffrey Aubé2, Laura M Bohn3.   

Abstract

Biased agonists of G protein-coupled receptors may present a means to refine receptor signaling in a way that separates side effects from therapeutic properties. Several studies have shown that agonists that activate the κ-opioid receptor (KOR) in a manner that favors G protein coupling over β-arrestin2 recruitment in cell culture may represent a means to treat pain and itch while avoiding sedation and dysphoria. Although it is attractive to speculate that the bias between G protein signaling and β-arrestin2 recruitment is the reason for these divergent behaviors, little evidence has emerged to show that these signaling pathways diverge in the neuronal environment. We further explored the influence of cellular context on biased agonism at KOR ligand-directed signaling toward G protein pathways over β-arrestin-dependent pathways and found that this bias persists in striatal neurons. These findings advance our understanding of how a G protein-biased agonist signal differs between cell lines and primary neurons, demonstrate that measuring [35S]GTPγS binding and the regulation of adenylyl cyclase activity are not necessarily orthogonal assays in cell lines, and emphasize the contributions of the environment to assessing biased agonism.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30087177      PMCID: PMC6373773          DOI: 10.1126/scisignal.aar4309

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  73 in total

1.  6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment.

Authors:  Marie-Laure Rives; Mary Rossillo; Lee-Yuan Liu-Chen; Jonathan A Javitch
Journal:  J Biol Chem       Date:  2012-06-26       Impact factor: 5.157

2.  Kappa- and delta-opioids block sympathetically dependent hyperalgesia.

Authors:  Y O Taiwo; J D Levine
Journal:  J Neurosci       Date:  1991-04       Impact factor: 6.167

3.  The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo.

Authors:  Kate L White; J Elliott Robinson; Hu Zhu; Jeffrey F DiBerto; Prabhakar R Polepally; Jordan K Zjawiony; David E Nichols; C J Malanga; Bryan L Roth
Journal:  J Pharmacol Exp Ther       Date:  2014-10-15       Impact factor: 4.030

4.  Cloning and characterization of RGS9-2: a striatal-enriched alternatively spliced product of the RGS9 gene.

Authors:  Z Rahman; S J Gold; M N Potenza; C W Cowan; Y G Ni; W He; T G Wensel; E J Nestler
Journal:  J Neurosci       Date:  1999-03-15       Impact factor: 6.167

5.  U50,488H-induced internalization of the human kappa opioid receptor involves a beta-arrestin- and dynamin-dependent mechanism. Kappa receptor internalization is not required for mitogen-activated protein kinase activation.

Authors:  J G Li; L Y Luo; J G Krupnick; J L Benovic; L Y Liu-Chen
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

6.  Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons.

Authors:  Cullen L Schmid; John M Streicher; Chad E Groer; Thomas A Munro; Lei Zhou; Laura M Bohn
Journal:  J Biol Chem       Date:  2013-06-17       Impact factor: 5.157

7.  Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation.

Authors:  J W Polli; R L Kincaid
Journal:  J Neurosci       Date:  1994-03       Impact factor: 6.167

8.  Critical role of PDE4D in beta2-adrenoceptor-dependent cAMP signaling in mouse embryonic fibroblasts.

Authors:  Matthew D Bruss; Wito Richter; Kathleen Horner; S-L Catherine Jin; Marco Conti
Journal:  J Biol Chem       Date:  2008-05-28       Impact factor: 5.157

9.  Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.

Authors:  G Di Chiara; A Imperato
Journal:  J Pharmacol Exp Ther       Date:  1988-03       Impact factor: 4.030

10.  Approaches to Assess Functional Selectivity in GPCRs: Evaluating G Protein Signaling in an Endogenous Environment.

Authors:  Laura M Bohn; Lei Zhou; Jo-Hao Ho
Journal:  Methods Mol Biol       Date:  2015
View more
  13 in total

Review 1.  Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine.

Authors:  Chloe J Jordan; Jianjing Cao; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-19       Impact factor: 5.250

Review 2.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

3.  Partial ligand-receptor engagement yields functional bias at the human complement receptor, C5aR1.

Authors:  Shubhi Pandey; Xaria X Li; Ashish Srivastava; Mithu Baidya; Punita Kumari; Hemlata Dwivedi; Madhu Chaturvedi; Eshan Ghosh; Trent M Woodruff; Arun K Shukla
Journal:  J Biol Chem       Date:  2019-04-29       Impact factor: 5.157

Review 4.  Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics.

Authors:  Travis W Grim; Agnes Acevedo-Canabal; Laura M Bohn
Journal:  Biol Psychiatry       Date:  2019-10-31       Impact factor: 13.382

5.  Biased Opioid Receptor Ligands: Gain without Pain.

Authors:  Tyler C Beck; Thomas A Dix; Russell A Norris
Journal:  Trends Endocrinol Metab       Date:  2020-09-14       Impact factor: 12.015

6.  Discovery of μ,δ-Opioid Receptor Dual-Biased Agonists That Overcome the Limitation of Prior Biased Agonists.

Authors:  Jin Hee Lee; Suh-Youn Shon; Woojin Jeon; Sung-Jun Hong; Junsu Ban; Do Sup Lee
Journal:  ACS Pharmacol Transl Sci       Date:  2021-04-06

7.  Nanobody-enabled monitoring of kappa opioid receptor states.

Authors:  Tao Che; Justin English; Brian E Krumm; Kuglae Kim; Els Pardon; Reid H J Olsen; Sheng Wang; Shicheng Zhang; Jeffrey F Diberto; Noah Sciaky; F Ivy Carroll; Jan Steyaert; Daniel Wacker; Bryan L Roth
Journal:  Nat Commun       Date:  2020-03-02       Impact factor: 14.919

8.  Self-Administration of Entactogen Psychostimulants Dysregulates Gamma-Aminobutyric Acid (GABA) and Kappa Opioid Receptor Signaling in the Central Nucleus of the Amygdala of Female Wistar Rats.

Authors:  Sophia Khom; Jacques D Nguyen; Sophia A Vandewater; Yanabel Grant; Marisa Roberto; Michael A Taffe
Journal:  Front Behav Neurosci       Date:  2021-12-16       Impact factor: 3.617

Review 9.  A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists.

Authors:  Kendall L Mores; Benjamin R Cummins; Robert J Cassell; Richard M van Rijn
Journal:  Front Pharmacol       Date:  2019-04-17       Impact factor: 5.810

10.  Kappa opioid receptor and dynorphin signaling in the central amygdala regulates alcohol intake.

Authors:  Daniel W Bloodgood; J Andrew Hardaway; Christina M Stanhope; Dipanwita Pati; Melanie M Pina; Sofia Neira; Shivani Desai; Kristen M Boyt; Richard D Palmiter; Thomas L Kash
Journal:  Mol Psychiatry       Date:  2020-02-25       Impact factor: 13.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.